Amgen Inc
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Vectibix (panitumumab by Year
Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%)
Amgen Vectibix (panitumumab: 4.0% in FY2024, down 6.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“Sales increased 6% for the full year, driven by 8% higher net selling price and 4% volume growth, partially offset by unfavorable foreign exchange impact.”
Source: Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Reported in Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vectibix (panitumumab — Metastatic Colorectal Cancer) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | 4.0% | -6.0 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 10.0% | – | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
Cite this data
StockData. (2026). Amgen Vectibix (panitumumab (%), annual FY2023–FY2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-vectibix-vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.